Introduction
It is generally considered that the treatment of acute myeloid leukemia (AML) with conventional cytotoxic agents has reached its limits, with long-term survival still being achieved in less than 50% of cases. Increased understanding of the heterogeneous cytogenetic and molecular mechanisms underlying AML suggests that novel agents targeting individual molecular lesions, used either alone, in combination, or as an adjunct to conventional chemotherapy, hold promise for future improvements. The drive for a targeted therapeutic approach has been given momentum by the remarkable success of the tyrosine kinase inhibitor imatinib mesylate in chronic myeloid leukemia (CML), 1 although, given its greater molecular heterogeneity, it is unlikely that any single targeted agent will achieve the same universal impact in AML.
The type III receptor tyrosine kinase FMS-like tyrosine kinase 3 (FLT3) is a potentially attractive therapeutic target in AML. FLT3 plays an important role in the development of normal multipotent stem cells and B-cells 2;3 and is overexpressed in the majority of cases of AML. [4] [5] [6] Activating mutations of FLT3, including internal tandem duplication (ITD) mutations within the juxtamembrane region 7 and single-base point mutations within the tyrosine kinase domain of the receptor (TKD-PMs) 8;9 are among the commonest molecular lesions so far described in AML with a combined prevalence of 31%. 10 Both types of mutation cause autophosphorylation of the receptor, leading to activation of downstream signaling pathways involved in regulation of transcription, proliferation and apoptosis. [11] [12] [13] The overexpressed wild type (WT) FLT3 receptor may also be activated in AML cells by endogenous co-expression of the FLT3 ligand. 14;15 FLT3 in both its mutated and WT configurations may thus contribute significantly to leukemogenesis although, for AML to occur, at least one further molecular event that is inhibitory to cell differentiation is likely to be required 16;17 The presence of a FLT3 ITD mutation is independently predictive of increased relapse risk and reduced overall survival. [18] [19] [20] For personal use only. on April 19, 2017 [26] [27] [28] [29] [30] Lestaurtinib (CEP701) is an orally-bioavailable indolocarbazole alkaloid compound that is synthetically derived from the bacterial fermentation product K252a. The compound is FLT3-selective, inhibiting phosphorylation of FLT3 with an IC 50 of 2-3nM, but that of other class III receptor tyrosine kinases with IC 50 s in excess of 500nM. Lestaurtinib is cytotoxic to human AML cell lines expressing both mutant and WT FLT3 and prolongs survival in a mouse model of FLT3/ITD leukemia. 21 The drug has been shown to have a low toxicity profile in animal studies, in healthy human volunteers and in cancer patients 31 where dose limiting toxicities were reported in one patient at 80mg twice daily (grade 3 nausea) and a further patient at 120mg twice daily (grade 3 hypotension). In a recentlypublished phase 1/2 clinical trial, lestaurtinib was used at doses of 40- 
Study design
The study was a multicenter, open-label phase II trial of single agent lestaurtinib. twice daily from day 29 in the absence of significant drug-related toxicity. Dose reduction to 40mg twice daily was permitted at the discretion of the treating physician in the presence of unacceptable toxicity, or when the study drug was restarted following recovery from grade 3/4 non-haematological toxicity.
Following the completion of treatment, responding patients had the opportunity of continuing lestaurtinib until evidence of disease progression.
Assessment of toxicity and response
Patients were monitored at least weekly for the duration of the study. Safety assessments included evaluation of adverse events and vital signs, routine hematological and biochemical tests, clinical review and physical examination.
Toxicity was graded according to the National Cancer Institute (NCI) Common Toxicity Criteria version 2.0. Response to treatment was assessed by weekly peripheral blood examination, and bone marrow examinations on study days 14, 28 and 56. Standard criteria were used to define complete remission (CR) and partial remission (PR) respectively as a decrease in marrow blasts to less than 5% (CR), and a greater than 50% decrease in marrow blasts to 5-25% (PR) in a marrow of sufficient cellularity, with peripheral neutrophil count of >1x10 9 /l and platelet count of >100x10 9 /l, where these changes were maintained for at least 4 weeks. 36 The plasma inhibitory activity (PIA) for FLT3 from patients treated with lestaurtinib was assessed using a 'surrogate ex vivo bioassay' as previously described. 28 Briefly, a clonal cell line expressing constitutively-phosphorylated TKD-PMs were detected in three cases, including one I836 deletion mutation (case 5), one D835Y mutation (case 19) and one previously-undescribed D835V, I836F, M837P three-codon triple point mutation (case 25). 38 Five patients were treated with hydroxyurea for a median of 10 days (range 6-20 days) before commencing lestaurtinib, none of these patients receiving lestaurtinib and hydroxyurea simultaneously.
FLT3 expression analysis

Toxicity
Lestaurtinib was generally well tolerated. Commonly observed toxicities included mild nausea (8 cases), emesis (5), constipation (5), diarrhea (6) and elevations in alkaline phosphatase concentration (13 achieved a greater than 50% reduction in bone marrow blasts with normalization of peripheral counts, but this response was maintained for only 14 days. In case 28 a reduction in bone marrow blasts to less than 5% was seen, but this was accompanied by persistent thrombocytopenia and bone marrow hypocellularity.
The majority of clinical responses were of short duration (median time to progression 25 days, range 14-270 days). Figure 1 illustrates typical hematological responses seen in two cases with activating mutations of FLT3.
Both of these patients were initially cytoreduced with hydroxyurea before commencing lestaurtinib and achieved complete clearance of blasts from the peripheral blood after the study drug was introduced. Case 15 progressed rapidly after lestaurtinib was withdrawn due to toxicity, while case 19 achieved transfusion independence for 2 months prior to disease progression. In such cases it is difficult fully exclude the influence of hydroxyurea from the initial clinical response, this being an unavoidable consequence of the ethical requirement to use a non-experimental agent for cytoreduction to protect patients with high presenting WCC against the possibility of non-response. A similar overall response rate to lestaurtinib was seen, however, in patients that did not 
Correlative laboratory studies
A number of correlative laboratory assays were performed using patient bone marrow, peripheral blood and plasma samples obtained at trial enrollment and at day 14, 28 and 56 assessments to help understand the basis of the clinical activity of lestaurtinib in individual patients. 
FLT3 expression assays
Inhibition of FLT3 signaling
It is highly desirable that any clinical benefit attributed to lestaurtinib is assessed in the context of the degree of target inhibition achieved. Simple pharmacokinetic measurement of plasma drug concentration is unreliable as a surrogate of FLT3 inhibitory activity because lestaurtinib is highly protein bound with potentially wide variability in levels of free, active drug. Preclinical in vitro studies suggest that continuous inhibition of FLT3 autophosphorylation to below 15% of baseline activity is necessary to achieve a cytotoxic effect on leukemic blasts. Increases in lestaurtinib dose to 80mg twice daily disappointingly failed to increase FLT3 PIA levels to above 85% in any of the 5 cases that were reassessed having failed to achieve satisfactory inhibitory levels at the 60mg dose.
In vitro cytotoxicity assays
In vitro cytotoxic response of pre-treatment BM MNCs to lestaurtinib was assessed by MTS assay in 12 cases where adequate cell numbers were available ( Figure 6 ). Cytotoxic dose responses were highly heterogeneous: only one case (patient 27) demonstrated complete in vitro cytotoxic resistance to lestaurtinib, although 5 further cases, particularly those with clinically unresponsive disease, displayed relative lestaurtinib resistance, with more than 50% of blasts surviving at maximal drug concentrations.
Direct correlation of in vitro cytotoxic response data, in vivo FLT3 inhibitory activity (quantified by ex vivo bioassay) and clinical response data was possible in 10 cases, summarized in Table 5 . Sustained FLT3 inhibition to below 15% baseline activity was achieved in 7 of these 10 patients. Blasts from 2 of these 7 cases (cases 15 and 19) showed a significant in vitro cytotoxic response to lestaurtinib: these 2 patients also responded clinically. The other 5 cases For personal use only. on April 19, 2017 . by guest www.bloodjournal.org From displayed relative in vitro cytotoxic resistance to lestaurtinib and failed to respond clinically, suggesting that despite achieving adequate FLT3 inhibitory free plasma lestaurtinib levels, blasts from these patients were inherently resistant to the study drug. Contrastingly, although the 3 patients that failed to achieve sustained 85% FLT3 PIA (cases 1,2 and 10) also failed to respond clinically, the in vitro cytotoxic responses of blasts from these cases suggested a potential for clinical response if sustained plasma inhibitory concentration of lestaurtinib were to be achieved, for example by future dose manipulation.
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Discussion
The pre-clinical rationale to support the clinical use of FLT3 inhibitors in AML is strong. This study is the first clinical trial to examine the effects of FLT3 inhibitor monotherapy in AML patients whose disease has not failed prior chemotherapy.
It is also the first study of its kind to recruit patients irrespective of their FLT3 mutation status.
Oral lestaurtinib was generally well tolerated in this group of older patients, with reported toxicities being mild in comparison to those expected with traditional cytotoxic chemotherapy. The most commonly reported events were mild gastrointestinal side effects that were somewhat more marked following dose escalation to 80mg.
For the older AML age group under study, a typically representative population with a FLT3 mutation rate of 17% was recruited. The limited clinical responses to lestaurtinib were of a similar frequency, depth and duration to those reported in previous studies of FLT3 inhibitor monotherapy in relapsed/refractory patients with FLT3 activating mutations. [26] [27] [28] [29] [30] No complete or partial remissions were seen by standard criteria and the median time until evidence of disease progression was 25 days, although some more prolonged responses with extended transfusion independence were seen. It seems likely that any potential increase in drug-sensitivity to be expected from recruiting a previously-untreated population was offset by the selection of older patients with fewer FLT3 Lestaurtinib inhibits engraftment of FLT3/ITD stem cells in mice, suggesting a direct cytotoxic effect on stem cells 39 and it has been hypothesized that stemcell-directed therapeutic effects could underlie such delayed responses. 40 For personal use only. on April 19, 2017 . by guest www.bloodjournal.org From
